scholarly journals Tiotropium: efficacy and safety in pediatric bronchial asthma

2021 ◽  
pp. 175-180
Author(s):  
Natalia G. Kolosova ◽  
Irina V. Grebeneva ◽  
Veronika D. Denisova
Keyword(s):  
Children And Adolescents ◽  
Bronchial Asthma ◽  
Adjunctive Therapy ◽  
Randomized Clinical Trials ◽  
Inhaled Corticosteroids ◽  
Symptom Control ◽  
Asthma Treatment ◽  
Efficacy And Safety ◽  
Chronic Lung Diseases ◽  
Long Acting

Bronchial asthma is one of the most common chronic lung diseases observed in children. According to the international and Russian guidelines, the long-term objectives of asthma treatment in children and adolescents are to achieve good symptom control, minimize the risk of asthma exacerbations, reduce hospital admissions, decrease the use of short-acting bronchodilators, reduce restrictions in the airflow and side effects, and ensure that normal activity levels are maintained. The asthma treatment is based on the use of inhaled corticosteroids as a backbone therapy and addition of adjunctive therapy if the disease control is poor or worsening. Tiotropium bromide is the first anticholinergic drug that has been approved for children and adults with poorly controlled asthma and is currently used as a treatment option for moderate to severe bronchial asthma. Randomized clinical trials in children and adolescents with persistent bronchial asthma showed high efficacy and safety of tiotropium. The addition of tiotropium in the form of 2 inhalations of 2.5 μg once a day to the bronchial asthma therapy in children over 6 years old, including medium doses of inhaled corticosteroids, is a preferred and safe option to increase the therapy coverage compared to an increase of a dose of inhaled corticosteroids to high levels, regardless of the disease phenotype (In atopic, non-atopic bronchial asthma, bronchial asthma with obesity, etc.). Tiotropium adjunctive therapy may also be a therapeutic option for children using inhaled corticosteroids, who have asthma that does not respond well to long-acting β2-agonist therapy, or for those, who are worried about the safety of long-acting β2-agonists.

The new prospects of the inhalation therapy for bronchial asthma

2020 ◽  
Vol 30 (4) ◽  
pp. 473-484
Author(s):  
S. N. Avdeev ◽  
Z. R. Aisanov
Keyword(s):  
Clinical Trials ◽  
Bronchial Asthma ◽  
Randomized Clinical Trials ◽  
Inhaled Corticosteroids ◽  
Fixed Combination ◽  
Inhalation Therapy ◽  
International Literature ◽  
Dosing Regimen ◽  
Muscarinic Antagonist ◽  
Long Acting

Based on the latest new international literature data, the article considers the possibilities of fixed combinations of long-acting β2-agonist, long-acting muscarinic antagonist and inhaled corticosteroids in achieving the control of bronchial asthma (BA). Clinical advantages for a fixed combination of indacaterol, glycopyrronium and mometasone furoate one dosing regimen in the therapy of BA are presented based on the results of recently completed randomized clinical trials IRIDIUM and ARGON.

scholarly journals ASMANEX TWISTHALER - THE DRUG OF CHOICE AMONG INHALED CORTICOSTEROIDS

2013 ◽  
Vol 10 (6) ◽  
pp. 51-57
Author(s):  
T V Latysheva ◽  
E A Latysheva ◽  
O V Shubina
Keyword(s):  
Bronchial Asthma ◽  
Inhaled Corticosteroids ◽  
Control Methods ◽  
Efficacy And Safety ◽  
Prior Therapy ◽  
Asthma Symptoms ◽  
Drug Of Choice ◽  
Systemic Corticosteroids ◽  
Before And After ◽  
Baseline Therapy

Goals. To reveal the clinical efficacy and safety of Asmanex in patients with moderate and severe bronchial asthma (BA), treated with inhaled and/or systemic glucocorticosteroids (GCS), depending on the severity and level of control. Methods. 40 patients (age 18 to 65 years) were treated with Asmanex with equivalent to prior therapy with inhaled corticosteroids (ICS) doses or in combination with systemic corticosteroids prior therapy (without increasing the dose of systemic corticosteroids) for 3 months. Efficacy was assessed before and after the treatment on a background of Asmanex treatment by the need of additional using of agonists of β 2-adrenoreceptors, severity of daytime and nighttime asthma symptoms, dynamics of spirometry parameters. The efficacy of Asmanex was compared with the original baseline therapy of other inhaled corticosteroids at equivalent doses using the new delivery system.

Asthma: Anti-Immunoglobulin E Therapy with Omalizumab for Asthma

2007 ◽  
Vol 41 (9) ◽  
pp. 1397-1410 ◽  
Author(s):  
Leslie Hendeles ◽  
Christine A Sorkness
Keyword(s):  
Clinical Trials ◽  
Cost Effectiveness ◽  
Randomized Clinical Trials ◽  
Inhaled Corticosteroids ◽  
Immunoglobulin E ◽  
Data Extraction ◽  
Symptom Control ◽  
High Dose ◽  
Search Term ◽  
Ige Mediated

Objective: To evaluate data on anti-immunoglobulin E (anti-IgE) therapy for asthma. Data Sources: Information was selected from PubMed from 1989 to May 2007 using the search term omalizumab and included randomized, controlled trials. These studies evaluated asthma treatment with omalizumab and focused on its efficacy, tolerability, and cost-effectiveness in this population. Study Selection and Data Extraction: All randomized clinical trials were reviewed (23 were identified and 19 were included; 3 were not relevant and 1 contained duplicative data). Other articles using the search words anti-IgE therapy and cost-effectiveness were evaluated; relevant information was extracted. Data Synthesis: IgE-dependent mechanisms play an important role in the development and maintenance of airway inflammation in asthma. Omalizumab is a subcutaneously administered monoclonal anti-IgE antibody that reduces unbound IgE concentrations and promotes down-regulation of IgE receptors. Results from clinical trials in adults, adolescents, and children with poorly controlled IgE-mediated asthma have shown that omalizumab improves symptom control and allows patients to be managed with lower doses of inhaled corticosteroids (ICS). It has been well tolerated in clinical trials lasting as long as 52 weeks, but injection-site reactions are common (45% in omalizumab group vs 43% in placebo group) and anaphylaxis has occurred in 0.2% of patients. A consensus expert panel has recommended that omalizumab should be considered for patients 12 years of age or older with allergic asthma who are inadequately controlled on guideline-based therapy and require maintenance therapy with systemic corticosteroids or high-dose ICSs, or who have poor adherence to ICS therapy. Conclusions: Anti-IgE therapy provides an effective and generally safe approach to the treatment of patients with IgE-mediated asthma who are not adequately controlled by conventional guideline-based medications. However, the potential benefit must be weighed against the cost and inconvenience of this new therapy.

scholarly journals Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma

2018 ◽  
Vol Volume 12 ◽  
pp. 1093-1106 ◽  
Author(s):  
Eric D. Bateman ◽  
Christopher O'Brien ◽  
Paul Rugman ◽  
Sally Luke ◽  
Stefan Ivanov ◽  
...  
Keyword(s):  
Inhaled Corticosteroids ◽  
Atopic Asthma ◽  
Efficacy And Safety ◽  
Beta 2 ◽  
Long Acting

Stimulant treatment for children and adolescents with ADHD - An update on efficacy and safety issues

2011 ◽  
Vol 26 (S2) ◽  
pp. 2144-2144
Author(s):  
T. Banaschewski
Keyword(s):  
Children And Adolescents ◽  
Pharmacological Treatment ◽  
Treatment Plan ◽  
Comprehensive Treatment ◽  
Efficacy And Safety ◽  
Pharmacological Management ◽  
Stimulant Treatment ◽  
Safety Issues ◽  
Group A ◽  
Long Acting

Pharmacological management for children and adolescents with ADHD should be part of a comprehensive treatment plan including psychological, behavioural, and educational advice and interventions. If pharmacological treatment is appropriate, stimulant medications and atomoxetine are the most effective medications for ADHD. The European ADHD Guidelines Group (a panel of ADHD experts from several European countries) has developed guidelines for the diagnosis and treatment of ADHD and published algorithms on the use of long-acting medications. Recently, the Guidelines Group has conducted a comprehensive review of the published literature on adverse effects of the drugs that are licensed in Europe, and most commonly used, for the treatment of ADHD or hyperkinetic disorder. This presentation will summarize those results and give an update on efficacy and safety issues concerning the pharmacological treatment of children and adolescents with ADHD.

scholarly journals THE EFFICACY AND SAFETY OF FOSTER IN PATIENTS WITH BRONCHIAL ASTHMA IN ROUTINE CLINICAL PRACTICEon behalf of the Research Group «ESTAFETA» to assess the efficacy and safety of the drug «Foster» in patients with asthma in routine clinical practice

2009 ◽  
Vol 7 (5) ◽  
pp. 82-90
Author(s):  
N I Iljina ◽  
K S Pavlova
Keyword(s):  
Asthma Control ◽  
Bronchial Asthma ◽  
Fixed Combination ◽  
Combined Therapy ◽  
Persistent Asthma ◽  
Innovative Technology ◽  
Symptomatic Therapy ◽  
Efficacy And Safety ◽  
Inhaled Steroids ◽  
Long Acting

Background. Evaluation of the efficacy and safety of the drug Foster (fixed combination of beclomethasone di-propionate 100 mcg and formoterol 6 micrograms per single dose) in metered-dose aerosol inhaler technology Modulite® in patients with bronchial asthma (BA). Methods. Prospective non comparative multicenter open observational study. Study group consisted of 120 practicing physicians from the 92 hospitals in 21 cities of Russia. Analyzed 557 case report forms of patients with moderate persistent asthma treated with Foster during 12 weeks who needed to correct the basic therapy (according to asthma control criteria GINA 2006). Results. The effectiveness of treatment with Foster was observed in 555 (99,6%) of 557 patients, who showed improvement in lung function, decreased severity of symptoms, reducing the need for symptomatic therapy compared with baseline and improved asthma control in general. Conclusions. In most cases, control over moderate and severe persistent asthma can be improved by the combined therapy of inhaled steroids (ICS) and в2-agonist long-acting (LABA). In this case, Foster is a drug of choice with a fixed combination of ICS and LABA. Extra-fine form of the drug (thanks to innovative technology Modulite®) is evenly distributed in central and peripheral airways, providing good therapeutic effect of using of low doses of ICS and reducing the likelihood of side effects.

Sign in / Sign up

Export Citation Format

Share Document